Bayer stock steadies as 2026 outlook and Roundup litigation remain central

Bayer stock remains a litigation-and-earnings story on 17 July 2026, with the company still guided by its 2026 outlook and the market still focused on the legal overhang around Roundup. Bayer (ISIN DE000BAY0017) has framed 2026 around sales of EUR 46 billion to EUR 48 billion, EBITDA before special items of EUR 9.7 billion to EUR 10.2 billion, and core earnings per share of EUR 4.80 to EUR 5.30.

EUR 46 billion to EUR 48 billion

The guidance range gives investors a clear reference point: the midpoint implies sales of EUR 47 billion and EBITDA before special items of EUR 9.95 billion for 2026. That matters because the same outlook also calls for core earnings per share of EUR 4.80 to EUR 5.30, a range that will be judged against the company’s legal costs and operating recovery.

The business mix still matters, but the stock now trades less on the broad pharma and crop-science story than on whether the 2026 targets can absorb litigation volatility. A tighter earnings range would strengthen the case for stability; a weaker one would keep the market centered on cash generation.

Litigation still sets the tone

Roundup remains the main legal issue around Bayer, and the company’s U.S. litigation exposure continues to shape how investors read every earnings update. That is why the 2026 EBITDA and EPS targets matter more than usual: they are the easiest measurable test of whether operations are offsetting legal pressure.

Bayer also continues to carry a large operational scale, with the 2026 sales target centered on roughly EUR 47 billion at the midpoint. The comparison is straightforward: sales guidance of EUR 46 billion to EUR 48 billion, EBITDA before special items of EUR 9.7 billion to EUR 10.2 billion, and core EPS of EUR 4.80 to EUR 5.30 create a compact set of numbers that investors can track through the year.

Products still matter

In pharmaceuticals, Bayer’s key products and pipeline remain important because they support the earnings base behind the 2026 targets. In crop science, the company’s ability to defend margins is just as relevant, because the guidance assumes the group can keep the operating engine intact while handling legal costs.

The stock closing reference is the company’s 2026 plan rather than a fresh quote: sales of EUR 46 billion to EUR 48 billion, EBITDA before special items of EUR 9.7 billion to EUR 10.2 billion, and core EPS of EUR 4.80 to EUR 5.30 all remain the numbers that define the investment case.

2026 numbers define the stock

Bayer’s current narrative is built around measurable targets, not vague promises. The market’s main test is whether the company can deliver EUR 47 billion at the midpoint of sales guidance while protecting EBITDA before special items near EUR 9.95 billion and core EPS near EUR 5.05.

That combination keeps Bayer stock tied to execution across the rest of 2026, with the legal overhang and operating performance still moving together.

Bayer financial snapshot

• Company: Bayer AG
• ISIN: DE000BAY0017
• Ticker: XETRA: BAYN
• Trading venue: Xetra
• Sector / Industry: Health Care / Pharmaceuticals and life sciences
• Index membership: DAX
• Next earnings date: 7 August 2026